SLAS2026 Solutions Spotlight Theater
Solutions Spotlights are 20-minute presentations by exhibitors that highlight a new technology or a customer case study.
Key:
Complete
Next
Failed
Available
Locked
FORMULATRIX - Where Computation Meets Chemistry: Formulatrix Liquid Handling as the Execution Layer for Machine-Learning Drug R&D
Open to view video. | Closed captions available
Open to view video. | Closed captions available
As machine-learning workflows take a larger role in drug discovery, the bottleneck has shifted from prediction to physical execution: turning model-generated plans into precise, reliable wet-lab actions. This talk covers how the FORMULATRIX liquid-handling portfolio—the MANTIS, TEMPEST, F.A.S.T., and FLO i8 PD—provides an AI-friendly execution layer for closed-loop R&D at highly miniaturized volumes.
The MANTIS and TEMPEST deliver ultra-low-volume, high-precision dispensing that supports rapid, low-cost iteration of assay conditions. Their open API has been used to integrate these systems in many automated workflows over the past 10+ years. The F.A.S.T. extends this low-volume expertise using positive-displacement tips with superb sub-microliter accuracy down to 0.1 µL and a new expanded range up to 50 µL. The redesigned FLO i8 PD adds non-contact dispensing (NCD) to 8 independently controlled channels that can access a wide range of labware, handling transfer volumes from 1 mL down to 200 nL NCD droplets for maximum workflow flexibility in a single system. The REST API of the FAST and FLO enables easy integration and direct control from ML-driven orchestration tools.
Together with our industry-leading support team, these systems offer a precise and reliable physical layer that computational pipelines can trust. Each instrument reports detailed dispense metrics and run data, ensuring that model-directed experiments are executed as intended and can be reproduced. This execution fidelity is what ultimately enables machine-learning models to close their experimental loops at speeds and scales that meaningfully accelerate drug discovery.
REVVITY HEALTH SCIENCES - Enhancing laboratory reproducibility with the AssayMate™ workstation: budget automation performance for consistent, traceable results.
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Laboratory reproducibility remains a critical challenge in life sciences research, with studies indicating that inconsistent liquid handling is a major contributor to experimental variability. The AssayMate workstation addresses these concerns through automation that delivers consistent data across operators and experiment reports.
This tutorial will demonstrate how the AssayMate system's error detection, real-time protocol visualization, and easy drag-and-drop software directly tackle some of the reproducibility issues. Key features including pressure-based liquid level detection, collision detection, and optional environmental control modules will be showcased through protocol examples.
The session will include a recorded demonstration of protocol development using the intuitive AssayPREP™ software. During this tutorial, attendees will learn to:
• Develop and implement automated methods ready to use for the system’s users
• Establish protocol traceability with documentation and logs of experimental runs
• Maintain precision standards that meet the reproducibility requirements for publishable research
• Identify and mitigate key sources of experimental variability through proper automation setup and environmental control modules
For research use only. Not for use in diagnostic procedures.
PEAPOD BIO - Now you see it! Visualizing the previously invisible with high-throughput mass spectrometry
Open to view video. | Closed captions available
Open to view video. | Closed captions available
High-throughput screening by mass spectrometry (MS) offers direct and label-free readouts to accelerate small molecule drug discovery. Yet many analytes remain impossible to detect due to ion suppression, matrix interference, and unresolvable peaks that leave many targets in the dark. Join Peapod Bio as we present polymeric enrichment arrays (PEAs) that integrate seamlessly with MALDI MS to solve these historical challenges. With a throughput of > 100,000 compounds per day, a next-generation affinity selection mass spectrometry (ASMS) platform capable of measuring small molecule binding and ternary complex formation, and resolving overlapping peaks, Peapod Bio’s proprietary platform is opening new avenues to screen biochemical activities and binding interactions to deliver lead compounds for even the most challenging targets with confidence.
HAMILTON - Scaling capacity, precision and efficiency: Automation as a strategic lever in Molecular Diagnostics
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Lynn will explore how automation is not just a tool but a strategic lever, reshaping diagnostic capacity, accelerating turnaround times, and ensuring accuracy at scale. Attendees will gain insights into the evolving role of automation in molecular diagnostics and how it can drive both scientific and operational excellence.
HIGHRES BIOSOLUTIONS - AI-Enabled Orchestration for the Intelligent Lab
Open to view video. | Closed captions available
Open to view video. | Closed captions available
HighRes accelerates life science discovery by delivering intelligent data and lab automation solutions that empower research teams to execute efficient, reproducible science. Drawing on over 20 years of experience in high-throughput laboratory automation, HighRes addresses critical bottlenecks in modern labs (e.g., fragmented data systems, lack of workflow standardization, and reactive planning processes) through an integrated platform ecosystem.
The Cellario Platform combines workflow orchestration (CellarioOS), AI-powered assistance (CellarioCopilot), and digital lab design (CellarioLabs) with proprietary codified knowledge (Cerebro) built from two decades of scientific workflow expertise. This architecture enables scientists to plan and visualize lab spaces in 3D, translate scientific intent into executable protocols using natural language AI, and automatically capture normalized operational and scientific data across 500+ validated instruments.
HighRes solutions are designed for accessibility and scalability, offering flexible deployment options from plug-and-play systems to open APIs that allow labs of any size to start small and scale as needed. The platform's modular, device-agnostic architecture ensures seamless integration with existing LIMS, ELNs, and informatics systems while providing real-time visibility across multi-lab, multi-instrument operations. By bridging the gap between scientific planning and execution, HighRes delivers the intelligent lab of the future today, enabling faster breakthroughs through operational excellence.
CARTERRA - Compressing Drug Discovery Timelines with HT-SPR Technology
Open to view video. | Closed captions available
Open to view video. | Closed captions available
High-throughput surface plasmon resonance (HT-SPR) has transformed the deployment of real-time, label-free binding measurements in drug discovery. Building on Carterra’s established one-on-many HT-SPR platforms, Carterra’s new platform enables high-throughput analysis in the many-on-few format by profiling 48 analytes simultaneously. The examples presented here demonstrate how this new platform accelerates the drug discovery process by (1) enabling hit identification, validation, and selectivity assessment within a single experiment completed in hours instead of days, and (2) allowing larger panels of lead compounds to be evaluated earlier in the optimization workflow. These advances redefine the role of HT-SPR in early-stage drug discovery by enabling faster, broader, and more information-rich decision-making.
UNION BIOMETRICA - Large particle imaging flow cytometry for spheroids, organoids and the NAMs initiative
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Organoids, spheroids, and microtissues hold the promise to provide human-relevant insight, yet most NAMs programs still rely on manual picking, low-throughput imaging, and inconsistent QC that can stall scale-up and challenge reproducibility. Union Biometrica, Inc.’s large particle flow cytometry technology is the only high-throughput platform designed to analyze and sort intact 3D biological structures – hundreds of microns in size – without destroying them. COPAS and BioSorter instruments can sort live organoids, spheroids, and microtissues based on size, morphology, fluorescence, viability, or engineered reporters while keeping them intact and functional. This instrumentation allows experiments and assays to scale from dozens to tens of thousands of organoids per run, accelerating screening, culturing processes, disease modeling, differentiation optimization, and QC workflows. With this technology researchers can standardize their 3D biology with consistent, quantifiable inputs, which are critical for regulatory acceptance of NAMs data. COPAS Vision flow cytometer also collects brightfield images of the analyzed cell clusters. Automating the analysis and handling of the cell clusters eliminates subjective, manual picking, and therefore reduces variability in organoid-based assays.
FORMULATRIX - Scaling Lab Automation: Customer-Driven Insights from Rover, Cellmatic, and Stack
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Formulatrix is reshaping laboratory operations with automation platforms designed to simplify routine tasks and support labs as their workflow needs grow. Stack introduces a new generation of modular automation infrastructure that leverages vertical space, offers rapid installation, and incorporates hands-free calibration, allowing laboratories to build and expand automation pods with unprecedented ease. Rover provides autonomous plate handling that connects instruments across the lab and bridges gaps between “islands of automation” to create more coordinated, continuous workflows. Cellmatic is a specific, application-focused integration that couples Formulatrix’s transportation devices and instrumentation with a carefully constructed application-driven UI and scheduler to provide an off-the-shelf system for adherent cell culture.
This presentation will highlight these technologies alongside insights gathered from early customer installations. These real-world examples have revealed meaningful gains in consistency, uptime, and throughput, while also highlighting practical considerations such as space utilization, protocol adaptation, and the role of the Formulatrix applications team in tailoring workflows to real-world needs. These in-field learnings continue to inform the evolution of the automation portfolio—ensuring that Rover, Cellmatic, and Stack grow in alignment with customer expectations and collectively advance a more connected, efficient, and scalable vision of laboratory automation.
CORNING LIFE SCIENCES - De-Risking CNS Drug Discovery with AI-Powered Human Brain Organoids
Open to view video. | Closed captions available
Open to view video. | Closed captions available
BrainStorm Therapeutics is harnessing patient iPSC-derived brain organoids to model complex neurological diseases with unprecedented accuracy. Traditional animal and cell models often fail to capture the intricacies of human brain biology, limiting therapeutic success. Our platform generates 3D brain organoids from patient iPSCs that faithfully recapitulate disease-relevant cell types, neural circuits, and phenotypes, including dopaminergic neuron loss and lipid metabolism defects seen in Parkinson’s disease. These models serve as a foundation for high-content screening, transcriptomic profiling, and functional analysis, enabling us to uncover both generalizable and mutation-specific disease mechanisms. By layering in AI tools trained on multimodal biological data, we enhance our ability to map dysregulated pathways and prioritize therapeutic targets. Our “clinical trial in a dish” approach supports more predictive and patient-relevant drug testing, reducing cost and risk in early-stage R&D. We are extending this organoid-based platform to additional brain disorders like Rett Syndrome and CDKL5 Deficiency Disorder, with the goal of delivering precision treatments rooted in human biology.
HAMILTON - Beyond the UI: Empowering Chemistry Through Hamilton’s API-Driven Automation
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Automated chemistry often depends on liquid handling workflows that are more complex than what is easily supported through the native Microlab Prep UI. To build and scale these workflows, automation engineers need programmatic tools that enable deeper customization and integration. In this talk, we highlight how Hamilton’s Microlab Prep liquid handler and its newly released API make this possible by allowing engineers to develop methods programmatically in Python rather than relying solely on the standard UI. Programmatic access connects the Microlab Prep to a rich software ecosystem that streamlines and accelerates workflow development. Used alongside the familiar UI, the API allows the Microlab Prep to integrate seamlessly into modern automation pipelines and support more advanced, scalable chemistry workflows.
OMEGA BIOTEK - Addressing Large-Volume Plasmid Extraction Bottlenecks Through a Fully Automated Workflow
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Endotoxin-free plasmid DNA plays a crucial role in a range of sensitive downstream applications, including vaccine development, in vitro transcription, sensitive cell transfection, and mRNA-based therapeutics, where trace amounts of endotoxin contamination can adversely impact experimental outcomes and reproducibility. Despite this need, endotoxin-free plasmid purification at larger volumes remains largely manual and time-intensive, and robust fully automated solutions are limited.
In this presentation, we will explore a fully automated workflow for the Mag-Bind® Endo-free Plasmid Midi Kit on the Dynamic Devices Lynx® platform for the purification of endotoxin-free plasmid DNA from bacterial pellets derived from up to 50 mL culture volumes. This solution can easily be scaled up to maxi- and mega-scale plasmid preparations by splitting the sample across different wells of the plate and combining the eluates in the end to achieve maxi- or mega-scale yields.
REVVITY HEALTH SCIENCES - Overcoming Key Challenges in ADC Screening - From Biologics Liquid Handling to Mechanism Elucidation
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Antibody-drug conjugates have potential for application in oncology, combining antibody specificity with cytotoxic potency for targeted cancer therapy. However, ADCs present unique screening challenges beyond those of small molecules, including precise handling of viscous biologics, confirming target antigen expression across cell panels, and addressing variable internalization efficiency that directly impacts efficacy.
In this tutorial we discuss:
• Revvity's cell panel ADC screening platform that enables rapid evaluation of ADCs in both 2D and 3D assay formats across large, diverse cell line collections
• Target characterization approaches - antigen expression profiling across comprehensive cell panels to inform stratification strategies
• Liquid handling solutions - Revvity's FlexDropTM non-contact dispenser for precise, contamination-free delivery of viscous biologics
• ADC mechanism studies - internalization monitoring using Revvity's pHSenseTM reagents for real-time ADC cellular uptake tracking by plate reader or high content imaging
• Advanced screening strategies - optimal combination screen design for ADC plus standard therapy and bispecific ADC development, and pooled CRISPR approaches to identify response drivers and resistance mechanisms.
For research use only. Not for use in diagnostic procedures.
CENEVO - Advancing National Drug Discovery: Smarter, Scalable Compound Management at Compounds Australia with Cenevo
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Scaling operations to meet national demand while maintaining the flexibility to meet the diverse demands of a broad user base is a challenge for any research facility - Compounds Australia (Griffith University) has proven it can be done.
In this spotlight session, Compounds Australia will discuss how adopting Cenevo’s Mosaic sample management solution has improved operational efficiencies and prepared the facility for future expansion. Attendees will hear how connected digital systems like Mosaic can support more efficient, accurate, and future-ready laboratory operations.
As Compounds Australia grew, the facility’s in-house compound management system reached its limits; it could no longer be scaled or adapted to meet evolving scientific and operational requirements, nor meet the increasing need for real-time data access.
To continue delivering fast and reliable services, the team required a flexible and fully connected digital platform that could grow with the organization and keep pace with advancements in the sample management field.
Mosaic now provides Compounds Australia with a single environment for accurate sample tracking, access management for a range of open- and closed- sample libraries, integrated order to fulfilment tracking, and rapid access to data. It also integrates with key instruments and lab systems across the facility, reducing manual processing and supporting more consistent and scalable operations.
“We have probably reduced about 50% of the data handling time. Before, data turnaround could take one to two weeks. Now our clients receive their data before the plates even arrive.”
About Compounds Australia:
Compounds Australia, Australia’s national compound management facility located within Griffith University’s Institute for Biomedicine and Glycomics, manages high-quality compound collections that enable over 250 drug discovery projects annually. Since its establishment in 2008, Compounds Australia has gone through multiple, rapid growth cycles to meet the increased demand of local and international users. Today, the facility manages >1 million samples and supports the drug discovery research of ~60 member organisations.
About Cenevo:
Cenevo specializes in lab management systems, automation, orchestration, data management and AI technology. We are trusted by scientists, companies and research institutions worldwide, from small biotech to global pharma, with over 950 customers – including 8 out of the top 10 pharmas – and 45,000+ scientist users worldwide.
Cenevo enables connected labs that are automated, data-centric and AI enabled. Cenevo brings together Mosaic’s sample-centric lab operations with Labguru’s experimental-centric inventory, registration, ELN and LIMS technology. We empower scientists to do more science to deliver faster reproducible results, at a lower cost. Visit us at booth 1829.
OPENTRONS - Opentrons × NVIDIA: Extending Lab Automation into the Era of Physical AI
Open to view video. | Closed captions available
Open to view video. | Closed captions available
AI is rapidly reshaping biology, but progress is increasingly constrained not by models but by physical execution in the lab.
In this session, James Atwood (CEO, Opentrons) and Stacie Calad-Thomson (North America Business Development Lead, Healthcare and Life Sciences, NVIDIA) explore how laboratory automation is evolving in the age of Physical AI, where digital intelligence must reliably plan, execute, observe, and adapt in the real world.
While much of today’s AI ecosystem focuses on models, simulation, and prediction, the next frontier requires programmable, end-to-end execution of experiments, translating scientific intent into repeatable physical workflows and generating the execution data AI systems need to learn and improve.
Together, Opentrons and NVIDIA will discuss how open, software-defined lab automation enables this shift, connecting AI planning, perception, and robotics into closed-loop experimental systems. The session will highlight emerging approaches, such as multi-modal training with digital twins, that dissolve the boundary between intent and execution, and explore what this means for scalable, AI-native biology in drug discovery and beyond.
Attendees will also have the opportunity to sign up to participate in future Physical AI initiatives, contributing their expertise through hands-on demonstrations that help inform the next generation of intelligent laboratory systems.
This session offers a practical view into how Physical AI is moving from theory into the lab and why execution is becoming the critical leverage point for scientific breakthroughs.
CARTERRA - Redefining High-Throughput SPR
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Carterra transformed high-throughput surface plasmon resonance (SPR)–based antibody discovery with the launch of its one-on-384 array LSA platform in 2018. This newly developed platform substantially increases analyte throughput to 48 channels, with each channel containing two ligand spots and a reference. This presentation will introduce Carterra’s new system and demonstrate its functionality through two case studies. The first case study describes the use of the instrument’s 48-channel injections to simultaneously characterize binding kinetics and specificity of 48 monovalent antibodies against human and cynomolgus forms of a dimeric receptor. The second case study highlights high-throughput screening of a small-molecule library against a target and a counter-target, with rapid confirmation of hit compounds through titration experiments.
NCARDIA - Built for Discovery: Robust Screening Solutions Across Human iPSC-Derived Models
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Human induced pluripotent stem cell (iPSC)–derived models are transforming early drug discovery by providing physiologically relevant systems that better capture human biology. Built for Discovery: Robust Screening Solutions Across Human iPSC-Derived Models presents a suite of optimized, scalable assay platforms designed to enable reliable screening across multiple iPSC-derived cell types, including cardiomyocytes, neurons, and other specialized lineages. Through standardized differentiation processes, stringent characterization, and assay designs compatible with automation, we establish consistent performance and reproducibility across diverse applications. Examples highlight the integration of functional endpoints, multiplexed biochemical readouts, and kinetic measurements to deliver sensitive, translatable data. These solutions collectively demonstrate how robust iPSC-based systems can support hit identification, mechanism-of-action studies, and safety assessment with greater biological relevance. This work underscores the critical role of well-engineered, human-based screening models in accelerating drug discovery pipelines and improving confidence in early decision-making.
LICORBIO - In Vitro Avatars: 3D Bioprinted Colorectal Cancer Organoids for Clinical Decision Support
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Colorectal cancer (CRC) research and drug development remain constrained by preclinical models that lack reproducibility, scalability, and compatibility with quantitative imaging workflows. Although patient-derived organoids better reflect tumor biology, manual handling and endpoint assays can introduce variability that complicates drug-response analysis.
In this Solutions Spotlight, we present a 3D bioprinted CRC organoid platform that enables automated, uniform seeding across multiwell formats and supports scalable, image-based drug screening. Using non-toxic viability assays and quantitative whole-well imaging, we demonstrate proof-of-concept screening across chemotherapy, targeted, epigenetic, and immunotherapy agents.
This approach provides a reproducible, imaging-compatible solution for generating in vitro CRC avatars, enabling more robust drug-response assessment and supporting translational and clinical decision-support workflows.
HAMILTON - Refrigeration Reinvented: Sustainable Solutions Across Hamilton’s Automated Storage Portfolio
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Hamilton’s automated storage systems are now fully equipped with eco-friendly refrigeration technology—delivering compliance, sustainability, and cost savings. Discover how our solutions help you:
Cut energy use and reduce costs while meeting ESG requirements
Stay ahead of U.S. AIM Act and EU F-gas regulations for future-ready sample storage
Minimize downtime risks compared to conventional freezers
Gain added benefits like lower noise, longer lifespan, and improved serviceability
From compact –20 °C units to large-scale –80 °C automated systems, Hamilton will showcase technology leadership that empowers labs to meet today’s challenges and tomorrow’s goals.
DPX TECHNOLOGIES - Bead-Free Automated Cleanup and Size-Selection with DPX INTip Solutions for NGS Library Preparation
Open to view video. | Closed captions available
Open to view video. | Closed captions available
NiXTips® from DPX Technologies offer a streamlined alternative to magnetic bead-based methods by integrating proprietary silica media directly into automation compatible pipette tips for nucleic acid extraction, cleanup, and size selection suitable for NGS library preparation. This approach enables a simple bind–wash–elute workflow performed within the NiXTip without beads, magnets, or additional hardware. Unlike magnetic beads which require careful resuspension, magnet-based pelleting, and cold storage, NiXTips are handled like standard consumables, making them ideal for high-throughput automation. NiXTips eliminate issues such as bead carryover and laborious bead-based method optimization while reducing overall pipette tip waste. Additionally, NiXTips support rapid processing in 96 or 384 formats compatible with many automated liquid handling platforms.
LICORBIO - Modeling Early Neurodevelopmental Vulnerability to Zika Virus Using Cerebral Organoids
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Modeling neurotropic viral infections during human brain development is challenging due to limited access to fetal tissue and constraints in visualizing and quantifying large, three-dimensional systems. While cerebral organoids represent an immature model, this feature uniquely enables interrogation of early neurodevelopmental stages—when viruses such as Zika exert their most profound effects.
In this Solutions Spotlight, we present a human cerebral organoid model of Zika virus infection that leverages fetal-stage brain organoids to study infection-driven neurodevelopmental injury. We demonstrate sustained viral infection for over 20 days, followed by downstream tissue-level changes consistent with microcephaly-associated pathology. Large-area quantitative imaging is used to characterize organoid formation and growth, complemented by histological analyses to assess infection-induced structural alterations.
This workflow offers a scalable, imaging-compatible approach to investigating how neurotropic viruses impact the developing human brain in physiologically relevant 3D tissues.
TANGO BIOSCIENCES - Phage display in action: accelerating peptide, antibody, and molecular glue discovery through affinity, selectivity, and speed
Open to view video. | Closed captions available
Open to view video. | Closed captions available
The identification of high-quality, specific, and sensitive affinity reagents, including antibodies, antibody mimics, and peptides, remains a significant challenge in life science research, drug discovery, and diagnostics. Traditional approaches that rely on animal immunization are cumbersome and often prone to batch-to-batch variability. Screening technologies using cellular and/or organism models, such as yeast and bacteria, offer massive parallel screening workflows that overcome many of the caveats of traditional approaches, yet can also be restrictive and time-consuming. In this Spotlight Presentation, Tango Biosciences will showcase its innovative approach to phage display and how it is transforming the rapid discovery of peptides and antibodies for research and therapeutic applications. To date, we have built more than 25 high-quality libraries that support discovery efforts across a broad range of biomedical applications (e.g., inhibitor and radiochemical development, smart delivery of macromolecules). In this presentation, we will highlight our work on several biomedically relevant targets, including prostate-specific membrane antigen (PSMA), fibroblast activation protein (FAP), and HIV capsid protein p24. Finally, we introduce a proprietary multi-site discovery technology, called the Avidimer Platform, that offers an accelerated workflow for multimerized monobody, nanobody, and antibody discovery and showcases how it is ideally suited for the development of sandwich assays used in diagnostics and glue or targeted protein degradation discovery. Together, our flexible phage display solutions, combined with world-class phage libraries, enable the rapid discovery of diverse affinity reagents tailored to the needs of any project.
SCILLIGENCE CORPORATION - Transforming Compound Management and Lab Automation with AI + Scilligence Inventory
Open to view video. | Closed captions available
Open to view video. | Closed captions available
This presentation examines how artificial intelligence, together with the integrated informatics platforms Scilligence Inventory and Scilligence RegMol, is advancing compound management, laboratory automation, and results storage in pharmaceutical research.
We will show how Scilligence Inventory streamlines vial and plate management while offering programmatic interfaces to automated laboratory systems for material storage, sample preparation, and data capture. We will also highlight how Scilligence RegMol captures data and stores results for reporting, analysis, and insight.
The session will showcase how AI-powered Scilligence capabilities enhance laboratory operations, reduce manual touchpoints, and improve efficiency in data-driven research environments. By integrating Inventory and RegMol, researchers can create a continuous data flow from materials to instruments to results, which increases assay reproducibility and accelerates decision-making.
Attendees will learn practical strategies for:
• End-to-end tracking and management of laboratory test materials
• AI-powered integration between Inventory and laboratory systems
• Real-time access to results for reporting, analysis, and decision-making
MY GREEN LAB - Building a Global Culture of Laboratory Sustainability Through Transparency and Third-Party Verification
Open to view video. | Closed captions available
Open to view video. | Closed captions available
As expectations for environmental performance increase across the life-sciences sector, laboratories and suppliers need trusted, globally consistent sustainability standards.
This session highlights how My Green Lab and the ACT Ecolabel are enabling a global culture of laboratory sustainability through transparency, standardized metrics, and independent third-party verification. Together, these programs provide a common framework that aligns scientists, manufacturers, and procurement teams around credible, actionable sustainability data.
With adoption by nearly 5,000 laboratories in 54 countries, more than 60 leading product manufacturers, and 10 global sales channels, My Green Lab and ACT are setting the global standard for sustainable laboratory operations and product evaluation. Attendees will learn how transparency and verification drive measurable impact, support corporate sustainability goals, and accelerate sustainable decision-making without compromising scientific excellence while enhancing innovation.
BIO-RAD LABORATORIES - How to Automate Flow Cytometry and Gene Expression - Key Concepts and Considerations
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Automation in flow cytometry and gene expression analysis confers considerable benefits by improving both efficiency and accuracy within laboratory workflows. By reducing manual intervention, automation mitigates the risk of human error, resulting in more reliable and reproducible outcomes. The ZE5 Cell Analyzer and CFX Opus Real-Time PCR Systems exemplify Bio-Rad’s commitment to delivering robust solutions for automated flow cytometry and gene expression processes. This presentation will discuss key features that facilitate rapid data analysis, support seamless robotic integration, and drive increased productivity. Additionally, we will emphasize the importance of meticulous attention to detail in the design of application programming interfaces (APIs). We will also showcase several integration providers who have previously partnered with Bio-Rad on automation projects, to deliver the best possible outcomes for our shared customers.
SPT LABTECH - End-to-End Walkaway Automation of Watchmaker mRNA Library Prep on firefly®+
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Scientists from the Whitehead Institute GTC demonstrate an end-to-end, walkaway implementation of the Watchmaker mRNA library prep kit on SPT Labtech’s firefly®+. This session walks through the automated workflow, highlights how firefly operates in practice, and shows how reliable library generation can be achieved with minimal hands-on intervention.
AGILENT TECHNOLOGIES - The Next Generation of Hybrid Analysis: Expanding Possibilities in Automated Cell Imaging and Detection
Open to view video. | Closed captions available
Open to view video. | Closed captions available
For over a decade, the Agilent BioTek Cytation portfolio has served as the industry standard for combined multimode microplate reading and high-content cell imaging. This solutions spotlight offers an exclusive first look at the highly anticipated next-generation system joining the Cytation family. Developed in direct response to years of continuous customer feedback, the new platform is engineered to solve key laboratory challenges. Discover how the system's significantly enhanced imaging optics and powerful new features drive walk-away automation and expand assay possibilities. This evolution ensures researchers can acquire complex data faster and more efficiently than ever before, accelerating discovery from basic research to high-content screening.
AUTOMATA - The Robots are Taking Over! Don't Do More AI, Do More with AI. This is Next-Generation Automation Built for Real Transformation.
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Labs are being crushed by fragmented automation and brittle legacy frameworks that suppress science and require steep learning curves. Discover what is required to build an AI-native lab, built on modern data architecture, unified orchestration and adaptive intelligence that drives productivity and scales with the demands of next-generation R&D.
ALITHEA GENOMICS - 1536-DRUG-seq: Transcriptomics Platform for Ultra-Scalable Phenotypic Screening
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Modern drug discovery requires scalable experimental systems that generate high-quality, actionable phenotypic data suitable for integration with AI/ML–driven discovery pipelines. While transcriptomics-based profiling provides rich mechanistic insight, conventional RNA-seq workflows remain poorly suited to ultra-high-throughput profiling due to limitations in scalability and workflow complexity.
Here, we report MERCURIUS™ DRUG-seq technology, an RNA-extraction-free library preparation workflow that enables direct cells-to-library processing in 1536-well assay plates and seamless integration with automated liquid handling and acoustic dispensing systems. A complete experimental workflow, supported by transcriptomic data generated from four standard human cell lines, demonstrates robustness, reproducibility, and scalability across diverse cellular contexts. This approach significantly reduces reagent consumption, hands-on time, and per-sample cost while maintaining sensitivity for gene detection.
MERCURIUS™ DRUG-seq enables whole-transcriptome readouts at screening scale, supporting functionalization of large compound libraries. By expanding access to compound MoA profiling, safety assessment, and arrayed CRISPR perturbation studies, the platform enables generation of large, standardized, information-rich transcriptomic datasets that can directly inform decision-making and power AI-driven pharmaceutical development.
SARTORIUS - Automating Antibody Characterization on the Octet® BLI Platform: High-Throughput Epitope Binning
Open to view video. | Closed captions available
Open to view video. | Closed captions available
During the production of antibodies for therapeutics, reagents or vaccine development, generated libraries are screened to assess and determine candidate quality attributes such as titer, binding kinetics and other biophysical properties as a critical first step to enable the selection of promising ones early in the process. The screening of such libraries is often prohibitively expensive due to the amount of time it takes. By integrating the Octet high throughput RH96 instrument to a Biosero Robotic arm, a library of antibody clones generated from an H5N1 antigen for use in the development of reagents suitable for research focusing on the emergent avian flu from the HPAI H5N1 clade could be screened in an epitope binning competitive assay. Automation enabled the 72 x 72 binning matrix competitive assay to be completed unattended in as little as 18 hours.
ABIO - Beyond ELN and LIMS: Redefining Precision Science with Autonomous Workflows and a Unified Data Fabric
Open to view video. | Closed captions available
Open to view video. | Closed captions available
While laboratory hardware and lab research have advanced at breakneck speeds, R&D data management has largely failed to keep pace. This digital disconnect creates silos between wet and dry labs, hindering the scalability of modern discovery. To reach the "Lab of the Future," we must move beyond traditional ELN and LIMS toward an automation-native architecture.
In this spotlight, we introduce abio.ai, a suite of software products designed to bridge the R&D gap through four core pillars: Autonomous Lab Workflows, Augmented Intelligence, Precision Science, and a Trusted Data Fabric. We will explore how an Automation and AI-first approach enables seamless data flow across lab research and high-throughput execution.
Attendees will gain insights into the Abio Spark and Abio Blaze platforms, discovering how to unify disparate workflows into a single, cohesive ecosystem. Join us to learn how to architect a data-driven environment that empowers a smarter lab, better data, and bolder science.
YOKOGAWA CORPORATION OF AMERICA - Functional and Phenotypic Screening of Complex Intestinal Behaviors in Next-Generation iPSC-Derived Human Intestinal Organoids
Open to view video. | Closed captions available
Open to view video. | Closed captions available
Abstract: Induced pluripotent stem cell (iPSC) derived Human intestinal organoids (HIOs) hold tremendous promise for modeling disease and therapeutic response, yet most existing systems capture only a subset of intestinal biology and remain challenging to deploy in screening formats. At Intero Biosystems, we developed the next-generation of HIOs that recapitulate the major epithelial, mesenchymal, stromal, endothelial, neural, and smooth muscle–associated lineages of the intestine, yielding large, architecturally organized microtissues capable of complex functional behaviors. HIOs can also incorporate human immune cells, enabling interrogation of epithelial–immune crosstalk and inflammation-driven phenotypes in a controlled, physiologically relevant context. This multicellularity provides a uniquely human platform for studying inflammation, barrier dynamics, fibroblast-driven remodeling, and intestinal peristalsis outputs that are not measurable in conventional intestinal organoid models.
Traditional organoid methods rely on matrix embedding, which introduces heterogeneity, xenogenic components, variable mechanical properties, and interference with compound distribution and functional phenotypes. Our matrix-free culture format eliminates these sources of variability, producing more uniform microtissue geometry, improving reproducibility across batches, and enabling direct, unimpeded measurement of tissue-level phenotypes through quantitative imaging.
We integrate this matrix-free system with automated high-content screening on Yokogawa’s CQ1 and are transitioning to the CQ3000 for enhanced structural resolution and throughput. The CQ3000’s advanced imaging features,including a 20× 1.0 NA water-immersion objective for resolving multicellular architecture and high-speed acquisition up to 100 fps for deep integrative analysis of peristaltic function and immune-cell activity, are particularly well-suited for capturing emergent behaviors in these large HIOs. Automated acquisition and multiparametric analysis enable reproducible, plate-based phenotyping across thousands of HIOs, supporting true high-content screening with minimal manual intervention.